Kanada - angielski - Health Canada

pharmel inc - loxapine (loxapine succinate) - tablet - 2.5mg - loxapine (loxapine succinate) 2.5mg - miscellaneous antipsychotics

Kanada - angielski - Health Canada

pharmel inc - loxapine (loxapine hydrochloride) - solution - 25mg - loxapine (loxapine hydrochloride) 25mg - miscellaneous antipsychotics

Kanada - angielski - Health Canada

pharmascience inc - loxapine (loxapine succinate) - tablet - 2.5mg - loxapine (loxapine succinate) 2.5mg - miscellaneous antipsychotics

Kanada - angielski - Health Canada

pharmascience inc - loxapine (loxapine succinate) - tablet - 5mg - loxapine (loxapine succinate) 5mg - miscellaneous antipsychotics

Kanada - angielski - Health Canada

pharmascience inc - loxapine (loxapine succinate) - tablet - 10mg - loxapine (loxapine succinate) 10mg - miscellaneous antipsychotics

Kanada - angielski - Health Canada

pharmascience inc - loxapine (loxapine succinate) - tablet - 25mg - loxapine (loxapine succinate) 25mg - miscellaneous antipsychotics

Kanada - angielski - Health Canada

pharmascience inc - loxapine (loxapine succinate) - tablet - 50mg - loxapine (loxapine succinate) 50mg - miscellaneous antipsychotics

Unia Europejska - angielski - EMA (European Medicines Agency)

ferrer internacional s.a. - loxapine - schizophrenia; bipolar disorder - nervous system - adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. patients should receive regular treatment immediately after control of acute agitation symptoms.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

teva select brands - loxapine (unii: ler583670j) (loxapine - unii:ler583670j) - loxapine 10 mg - adasuve  is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults. “psychomotor agitation” is defined in dsm-iv as “excessive motor activity associated with a feeling of inner tension.” patients experiencing agitation often manifest behaviors that interfere with their care (e.g., threatening behaviors, escalating or urgently distressing behavior, self-exhausting behavior), leading clinicians to the use of rapidly absorbed antipsychotic medications to achieve immediate control of the agitation [ see  clinical studies ( 14 ) ] . the efficacy of adasuve was established in one study of acute agitation in patients with schizophrenia and one study of acute agitation in patients with bipolar i disorder [ see clinical studies ( 14 ) ] . limitations of use: as part of the adasuve rems program to mitigate the risk of bronchospasm, adasuve must be administered only in an enrolled healthcare facility [ see warnings and precautions ( 5.2 ) ] .

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

galen ltd - loxapine - inhalation powder - 9.1mg